EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies
Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.
Uncovering hidden genetic causes in adult cholestasis
Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.
Targeted gene sequencing panel resolves unexplained cholestasis in about 5% of adults
A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.
Researchers call for ICP to be included in hepatobiliary risk stratification
Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.
Genetic variants explain substantial proportion of undiagnosed cholestasis and hepatitis
Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.
AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis
Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
Genetic etiology may explain majority of adult-onset cholestatic disorders
Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.
Next generation sequencing may offer diagnoses in adult unexplained cholestasis
Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.
Novel panel identifies variants in unexplained cholestatic cases
A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
Predictive model with standard clinical parameters differentiates PSC and SSC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
NLP medical review may help identify adults with undiagnosed PFIC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
Contraceptives linked to unique cholestatic phenotype
Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.
Countdown to AASLD 2025: A preview with Deepak Joshi and Silvia Vilarinho
Dr Deepak Joshi and Dr Silvia Vilarinho discuss what’s ahead at AASLD 2025, focusing on late-onset genetic cholestasis and Alagille syndrome, and share what they are most looking forward to at this year’s meeting.
IBAT inhibitor case studies point to adult intrahepatic cholestasis benefits
Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis
Diagnosing and managing late-onset genetic cholestasis: a clinical pathway tool
A practical algorithm tool to help you navigate the different clinical presentations, reach an accurate diagnosis, and take optimal first management steps.
EASL guidelines offer ‘framework’ for intrahepatic cholestasis of pregnancy care
Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.
Pathogenic variants common in adult-onset cholestasis patients
Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.
Intrahepatic cholestasis of pregnancy EASL guidelines aid risk stratification
Ms Nina Rodriguez and Dr Tatyana Kushner confirm that the 2023 EASL guidelines can help risk stratify patients with intrahepatic cholestasis of pregnancy.
ABCB4 variant genotype–phenotype relationship in cholestasis elucidated
Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.
Genetic analysis aids diagnosis for atypical PFIC presentation
Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.
About late-onset genetic cholestasis
Richard Thompson provides a concise overview of late-onset genetic cholestasis, including the pathophysiology and genetics behind the various phenotypes that can present, in this short, animated video.
About late-onset genetic cholestasis
Richard Thompson provides a concise overview of late-onset genetic cholestasis, including the pathophysiology and genetics behind the various phenotypes that can present, in this short, animated video.
Unmet needs in late-onset genetic cholestasis: an expert discussion
This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
Whole-exome sequencing aids adult-onset cholestatic liver disease diagnosis
Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.
Whole-exome sequencing sheds light on unexplained adult-onset cholestatic liver disease
Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.
EASL guidelines direct genetic cholestatic liver management
An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
Breaking down PBC: a comprehensive guide
Led by Kris Kowdley, this interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) provides details on the pathogenesis, diagnosis, management and latest clinical data for PBC. Click through the sections, or download the PDF to use as a guide in your clinic.
Breaking down PBC: a comprehensive guide
Interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) providing details on the pathogenesis, diagnosis, management and latest clinical data.
PBC Clinical insights: evaluating therapeutic response and disease management
CME case study for the identification and management of Primary Biliary Cholangitis (PBC) including therapy response and disease management, for a 42 year old with abnormal liver blood test results.
